Oncology

Showing 15 posts of 310 posts found.

Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment

July 10, 2023
Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix

Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …

FDA grants Priority Review for Astellas Pharmaโ€™s BLA for cancer drug

July 6, 2023
Research and Development Astellas Pharma, Biologics License Application, FDA, GEJ, Oncology

Japanese pharmaceutical company Astellas Pharma has announced that the US Food and Drug Administration (FDA) has granted Priority Review for …

Jacobio Pharma receives CDE approval for pancreatic cancer study in China

July 5, 2023
Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial

Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasibโ€™s pivotal study for pancreatic cancer has been approved by …

Cytovation appoints Olav Hellebรธ to board of directors

July 5, 2023
Business Services Cytovation, Olav Hellebรธ, Oncology, appointment, board of directors

Cytovation ASA, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has …

lungs

AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC

July 3, 2023
Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …

Astellas establishes open innovation hub for tumour microenvironment research

June 29, 2023
Research and Development Astellas Pharma, Mitsui Fudosan, Oncology, open innovation hub, tumour microenvironment

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended …

national-cancer-institute-kluafqlacfw-unsplash

UK nonprofit National Cancer Research Institute to close

June 27, 2023
Medical Communications Cancer, NCRI, National Cancer Research Institute, Oncology, oncology

The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years of advancing cancer research. Established …

XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets

June 23, 2023
Sales and Marketing Cancer, Oncology, Xoma, acquisition, oncology

US-based biotechnology royalty aggregator XOMA has announced that it has gained the royalty and milestone rights for two assets from …

money_pills_2

Zymeworks to open new EU HQ in Dublin, Ireland

June 22, 2023
Business Services Dublin, Oncology, Zymeworks, headquarters, regulatory affiars

Canadian biotech company Zymeworks has announced plans to open its new Clinical and Regulatory EU headquarters in Dublin, Ireland. Zymework …

national-cancer-institute-kmvohcb-w5g-unsplash_1

FDA approves Pfizerโ€™s HRR mCRPC drug

June 21, 2023
Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer

US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …

Sirnaomics advances isSCC candidate into late-stage clinical development

June 20, 2023
Research and Development FDA, Oncology, Sirnaomics, clinical trial, isSCC

Global RNA therapeutics biopharmaceutical company Sirnaomics has announced that it has advanced its Squamous Cell Carcinoma in situ (isSCC) candidate …

Abu Dhabiโ€™s Department of Health, M42 and AbbVie enter strategic partnership

June 20, 2023
Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership

Abu Dhabiโ€™s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research …

GSK announces extension of FDAโ€™s review for momelotinib

June 20, 2023
Medical Communications FDA, GSK, Oncology, momelotinib, new drug application

GSK has announced that the US Food and Drug Administration (FDA) has extended its review period for the new drug …

document-428331_960_720

Nordic Bioscience receives FDA Letter of Support for biomarker in aggressive tumour fibrosis

June 16, 2023
Research and Development FDA, Nordic Bioscience, Oncology, Roche, tumour fibrosis

Danish biomarker company Nordic Bioscience has announced that the US Food and Drug Administration (FDA) has awarded it a Letter …

Takeda and HUTCHMEDโ€™s cancer drug shown to prolong overall survival

June 16, 2023
Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …

The Gateway to Local Adoption Series

Latest content